Wave of lawsuits in the USA: Bayer cuts dividend to a minimum due to financial worries. Bayer's existing best-in-class drugs will bring in less money due to patents gradually expiring, with no similarly lucrative follow-up drugs in sight.
Further extensive strategic measures are needed to repair the balance sheet. One such measure - which is probably also being discussed within the group - could be the sale of part of the company, in whole or in part. According to experts, only the consumer health sector involving over-the-counter medications is likely to be considered.